An application for phase 1 clinical trial of HLX37 independently developed by Fu Hong Hanlin (02696) in patients with advanced/metastatic solid tumors was approved by the NMPA

Zhitongcaijing · 12/01/2025 09:17

Zhitong Finance App News, Fu Hong Han Lin (02696) announced that recently, the application for phase 1 clinical trial (IND) of HLX37 (recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) (HLX37) independently developed by the company in patients with advanced/metastatic solid tumors was approved by the National Drug Administration (NMPA).